Pulmonary Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NTS with anti-HIF-1α activity may be a promising pharmacological agent for the treatment of pulmonary fibrosis.
|
29645000 |
2018 |
Pulmonary Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association between HIF-1α and LOX in regulating EMT during PQ-induced PF may be unidirectional.
|
29467842 |
2018 |
Pulmonary Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-1α triggers ER stress and CHOP-mediated apoptosis in alveolar epithelial cells, a key event in pulmonary fibrosis.
|
30560874 |
2018 |
Pulmonary Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that HIF-1α/PDK1-mediated glycolytic reprogramming is a critical metabolic alteration that acts to promote myofibroblast differentiation and fibrotic progression, and demonstrate that targeting glycolytic metabolism may prove to be a potential therapeutic strategy for the treatment of pulmonary fibrosis.
|
28915065 |
2018 |
Pulmonary Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, in primary myofibroblast-like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF-1α inhibitor (HIFi) decreased the expression levels of α-smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts.
|
28446589 |
2017 |
Pulmonary Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These studies support a potential role for HIF1A or ADORA2B antagonists in the treatment of IPF.-Philip, K., Mills, T. W., Davies, J., Chen, N.-Y., Karmouty-Quintana, H., Luo, F., Molina, J. G., Amione-Guerra, J., Sinha, N., Guha, A., Eltzschig, H. K., Blackburn, M. R. HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.
|
28701304 |
2017 |
Pulmonary Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism may function through miR-210-mediated repression of RUNX3, which further decreases the hydroxylation activity of PHD2, enhances the stability of HIF-1α, and promotes PQ-induced EMT, aggravating the progression of pulmonary fibrosis.
|
28699703 |
2017 |
Pulmonary Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our research aimed to determine whether the regulation of HIF-1α in EMT occurs via the Snail and β-catenin pathways in PQ poisoning-induced pulmonary fibrosis.
|
26781174 |
2016 |
Pulmonary Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of angiogenic factors (activation of VEGF through HIF-1A) may predispose to chronic course and lung fibrosis, whereas immunoangiostasis (related to an overexpression of inhibitory ING-4) may be involved in granuloma formation in early sarcoid inflammation, or sustained or recurrent formation of granulomas.
|
26022899 |
2015 |
Pulmonary Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More importantly, our results suggest an early primary role of HIF-1 in alveolar epithelial cell homeostasis and disease pathogenesis, provide insights on the pathophysiologic differences of different interstitial pneumonias, and indicate the importance of assessing the efficacy of pharmacologic inhibitors of HIF-1 activity in the treatment of pulmonary fibrosis.
|
17761615 |
2007 |